ES2145072T3 - Preparacion y usos de proteinas de membranas externas carentes de los de cocos gramnegativos. - Google Patents

Preparacion y usos de proteinas de membranas externas carentes de los de cocos gramnegativos.

Info

Publication number
ES2145072T3
ES2145072T3 ES94106827T ES94106827T ES2145072T3 ES 2145072 T3 ES2145072 T3 ES 2145072T3 ES 94106827 T ES94106827 T ES 94106827T ES 94106827 T ES94106827 T ES 94106827T ES 2145072 T3 ES2145072 T3 ES 2145072T3
Authority
ES
Spain
Prior art keywords
membrane proteins
gramnegative
coconuts
preparation
external membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94106827T
Other languages
English (en)
Inventor
Gary W Zlotnick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of ES2145072T3 publication Critical patent/ES2145072T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

AQUI SE DESCRIBE UN METODO PARA ELIMINAR LIPOOLIGOSACARIDOS (LOS) TOXICOS DE LAS MEMBRANAS EXTERIORES DE COCOS GRAM EGATIVOS, TALES COMO NEISSERIA MENINGITIDIS. PROTEINAS DE MEMBRANAS EXTERIORES VACIADAS DE LOS Y DE MEMBRANAS SOLUBLES EXTERIORES VACIADAS DE LOS PUEDEN SER PREPARADAS, LAS CUALES SON VALIDAS PARA EXTRAER ANTICUERPOS BACTERICIDAS CONTRA CEPAS HOMOLOGAS DE BACTERIA. VACUNAS Y OTROS USOS DE LAS PREPARACIONES SON DESCRITAS ADICIONALMENTE.
ES94106827T 1993-05-13 1994-05-02 Preparacion y usos de proteinas de membranas externas carentes de los de cocos gramnegativos. Expired - Lifetime ES2145072T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6158193A 1993-05-13 1993-05-13

Publications (1)

Publication Number Publication Date
ES2145072T3 true ES2145072T3 (es) 2000-07-01

Family

ID=22036711

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94106827T Expired - Lifetime ES2145072T3 (es) 1993-05-13 1994-05-02 Preparacion y usos de proteinas de membranas externas carentes de los de cocos gramnegativos.

Country Status (11)

Country Link
US (2) US6355253B1 (es)
EP (1) EP0624376B1 (es)
JP (1) JP3711289B2 (es)
KR (1) KR100355961B1 (es)
AT (1) ATE190502T1 (es)
CA (1) CA2123355C (es)
DE (1) DE69423383T2 (es)
DK (1) DK0624376T3 (es)
ES (1) ES2145072T3 (es)
GR (1) GR3033469T3 (es)
PT (1) PT624376E (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121427A (en) * 1994-10-24 2000-09-19 Connaught Laboratories Limited Major outer membrane protein CD of branhamella
EP0983342B1 (en) * 1997-05-28 2007-09-05 Novartis Vaccines and Diagnostics S.r.l. Culture medium with soy bean extract as aminoacid source and no protein complexes of animal origin
US20040087020A1 (en) 1997-05-28 2004-05-06 Chiron S.P.A. Culture medium with yeast or soy bean extract as amino acid source and no protein complexes of animal origin
DK0991761T3 (da) 1997-08-21 2008-05-19 Nederlanden Staat Hidtil ukendte mutaner af gramnegative mucosale bakterier og anvendelse deraf i vacciner
US20070026021A1 (en) * 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
EP2261355A3 (en) 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
ES2485940T3 (es) 1998-05-29 2014-08-14 Novartis Vaccines And Diagnostics, Inc. Combinación de vacunas contra Meningitis B/C
CN102580072A (zh) 1999-05-19 2012-07-18 诺华疫苗和诊断有限公司 组合式奈瑟球菌组合物
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
ES2507100T3 (es) * 2000-01-17 2014-10-14 Novartis Vaccines And Diagnostics S.R.L. Vacuna OMV suplementada contra meningococo
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US7301554B2 (en) * 2002-09-20 2007-11-27 Ricoh Company, Ltd. Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method
JP4697706B2 (ja) 2002-10-11 2011-06-08 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 高毒性髄膜炎菌系統に対する広範な防御のためのポリペプチド−ワクチン
CA2508912A1 (en) * 2002-12-06 2004-06-24 Agennix Incorporated Oral lactoferrin in the treatment of sepsis
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
US7608278B2 (en) 2003-12-30 2009-10-27 Wyeth Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability
GB0416120D0 (en) 2004-07-19 2004-08-18 Health Prot Agency Stable compositions containing OMV's
GB0419627D0 (en) * 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
NZ580974A (en) 2005-02-18 2011-05-27 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
LT2351772T (lt) 2005-02-18 2016-10-10 Glaxosmithkline Biologicals Sa Baltymai ir nukleorūgštys iš su meningitu/sepsiu susijusių escherichia coli
KR100612895B1 (ko) * 2005-05-04 2006-08-14 삼성전자주식회사 화학 물질을 이용한 생물학적 시료로부터 단백질의선택적인 제거 방법
WO2008020330A2 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
AR064642A1 (es) * 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
RU2477145C2 (ru) * 2008-05-30 2013-03-10 ДЗЕ Ю.Эс.Эй., ЭС РЕПРЕЗЕНТЕД БАЙ ДЗЕ СЕКРЕТАРИ ОФ ДЗЕ АРМИ, ОН БЕХАФ ОФ УОЛТЕР РИД АРМИ Мультивалентная вакцина из нативных везикул наружной мембраны менингококков, способы ее получения и применения
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
HRP20210242T4 (hr) 2010-08-23 2024-05-10 Wyeth Llc Stabilne formulacije antigena iz bakterije neisseria meningitidis rlp2086
CN103096920B (zh) 2010-09-10 2016-03-23 惠氏有限责任公司 脑膜炎奈瑟球菌orf2086抗原的非脂质化变体
GB201015132D0 (en) * 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
EP2613805B1 (en) * 2010-09-10 2019-10-23 GlaxoSmithKline Biologicals SA Meningococcus overexpressing nada and/or nhba and outer membrane vesicles derived therefrom
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
BR122016004924A2 (pt) 2012-03-09 2019-07-30 Pfizer Inc. Polipeptídeo isolado e composições imunogênicas compreendendo os mesmos
AU2013320313B2 (en) 2012-09-18 2018-07-12 Glaxosmithkline Biologicals Sa Outer membrane vesicles
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN106659717B (zh) 2014-08-22 2019-09-06 葛兰素史密斯克莱知识产权发展有限公司 用于治疗淋病奈瑟球菌感染的三环含氮化合物
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN110568116A (zh) * 2019-09-17 2019-12-13 广东医科大学附属医院 一种筛选用于诊断阿尔茨海默病的生物标志物的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271147A (en) 1980-01-10 1981-06-02 Behringwerke Aktiengesellschaft Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same
US4386066A (en) * 1981-08-20 1983-05-31 Merck & Co., Inc. Immunogenic complex from N. gonorrhoeae
WO1983003354A1 (en) 1982-03-30 1983-10-13 Us Army Neisseria gonorrhoeae vaccine
NL8403195A (nl) 1984-10-19 1986-05-16 Nederlanden Staat Immunogene complexen en vaccins die deze bevatten.
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
DE3516017A1 (de) 1985-05-02 1986-11-27 Jochen 1000 Berlin Kittel Verfahren zur herstellung membranstaendiger proteine aus biologischem material zur anwendung im biologischen systemen
US4707543A (en) 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
JPH01125328A (ja) * 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
EP0351604B1 (en) * 1988-06-29 1994-09-14 The Rockefeller University Neisserial vaccines
ATE120093T1 (de) 1988-12-19 1995-04-15 Praxis Biolog Inc Meningococcales klasse i-aussenmembranprotein- vakzin.
ES2063965T3 (es) 1989-03-09 1995-01-16 Praxis Biolog Inc Vacunas para haemophilus influenzae no tipificable.
JP2516841B2 (ja) 1989-04-14 1996-07-24 ユニリーバー・ナームローゼ・ベンノートシヤープ 抽出方法
US5552146A (en) * 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis

Also Published As

Publication number Publication date
KR100355961B1 (ko) 2002-12-26
DE69423383D1 (de) 2000-04-20
CA2123355C (en) 2007-08-28
EP0624376A1 (en) 1994-11-17
JPH0819396A (ja) 1996-01-23
US6921537B2 (en) 2005-07-26
DE69423383T2 (de) 2000-08-24
GR3033469T3 (en) 2000-09-29
JP3711289B2 (ja) 2005-11-02
US20020136741A1 (en) 2002-09-26
DK0624376T3 (da) 2000-07-24
PT624376E (pt) 2000-07-31
US6355253B1 (en) 2002-03-12
CA2123355A1 (en) 1994-11-14
ATE190502T1 (de) 2000-04-15
EP0624376B1 (en) 2000-03-15

Similar Documents

Publication Publication Date Title
ES2145072T3 (es) Preparacion y usos de proteinas de membranas externas carentes de los de cocos gramnegativos.
AU4841693A (en) Vaccines against group c neisseria meningitidis
Kim et al. Characterization of Antigens from Aspergillus Fumigatus: I. Preparation of Antigens from Organisms Grown in Completely Synthetic Medium
DK593285D0 (da) Polysaccharidforbindelse og fremgangsmaade til fremstilling deraf
YU24391A (sh) Poboljšana meningokokna polisaharid kon-jugovana vakcina
DE69941574D1 (de) Immunogenes beta-propionamido-gebundenes polysaccharid-protein konjugat geeignet als impfstoff und hergestellt bei verwendung von n-acryloyliertem polysaccharid
WO1990006696A3 (en) Meningococcal class 1 outer-membrane protein vaccine
DK1051506T3 (da) Fremgangsmåde til ekstraktion og isolation af bakterielle kapsel-polysaccharider til anvendelse som vaccine eller sammenkoblet med proteiner som konjugerede vacciner
DK0527760T3 (da) Fremgangsmåder og præparater til vaccination mod HIV
EP0313378A3 (en) Methods and compositions for transient elimination of humoral immune antibodies
DK0754055T3 (da) Gruppe A-streptokok-polysaccharid-immunogen-præparater og metoder
HUT35521A (en) Process for preparing a pharmaceutical composition containing a purified, detixicated endotoxine and a pyridine soluble extract of a microorganism
DK0480949T4 (da) Fremstilling af virusvaccine
EP0080021B1 (en) Haemophilus influenzae type b and pertussis outer membrane component combined vaccine
Bromuro et al. Differential release of an immunodominant 65 kDa mannoprotein antigen from yeast and mycelial forms of Candida albicans
IT1254360B (it) Epitopi immunologicamente omologhi di hla e proteine del virus hiv.
Vijay et al. Studies on Alternaria Allergens: V. Comparative Biochemical and Immunological Studies of Three Isolates of Alternaria tenuis Cultured on Synthetic Media
ES466359A1 (es) Procedimiento para preparar vacunas vivas e inactivas del virus de la rabia.
KR900702045A (ko) 천연 hiv gp 160의 제조방법
ES447313A1 (es) Un procedimiento de aislamiento de pilos de n. gonorrhoeae.
WO2001028583A3 (en) Melanoma vaccine and methods of making and using same
WO2002038611A3 (en) Method of producing antibodies by immunization with conjugates of molecules coupled to charge-modified proteins
RU2542393C2 (ru) СПОСОБ ПОЛУЧЕНИЯ КОНЪЮГАТА КАПСУЛЬНОГО ПОЛИСАХАРИДА Haemophilus influenzae ТИП b (Hib) C АНТИГЕНАМИ ДЛЯ СОЗДАНИЯ ИММУНОБИОЛОГИЧЕСКИХ ПРЕПАРАТОВ
Okuda et al. Immunologic cross-reactivity of Escherichia coli B envelope glycoproteins with some animal and plant cell membrane proteins
WO2023172741A3 (en) A multiple antigen presenting system (maps)-based staphylococcus aureus vaccine comprising b- and t-cell antigens, immunogenic composition, and uses thereof

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 624376

Country of ref document: ES